Physician profile
Jasmine E Dorsey
NPI 1205149325
$2,056.13
in general payments reported to CMS, 2019-2025
32 companies · $17.33 in 2025
The $17.33 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $140 · 2021: $178 · 2022: $732 · 2023: $501 · 2024: $80.15 · 2025: $17.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $598.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $434.30 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Xeris Pharmaceuticals, INC. | $333.54 | 2021-2023 | Gvoke Hypopen |
| Amarin Pharma, INC. | $142.88 | 2020-2021 | |
| Pfizer INC. | $133.42 | 2023-2024 | |
| Astellas Pharma US INC | $111.65 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $105.00 | 2022 | |
| Lilly USA, LLC | $66.01 | 2022 | |
| Janssen Pharmaceuticals, INC | $57.71 | 2020-2022 | |
| Amgen INC. | $56.62 | 2019-2023 | Otezla, Repatha |
| Abbott Laboratories | $55.81 | 2022-2023 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $43.23 | 2019 | |
| Abbvie INC. | $42.31 | 2022 | |
| Neurocrine Biosciences, INC. | $39.66 | 2024-2025 | Ingrezza |
| Dexcom, INC. | $36.30 | 2019-2023 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $33.30 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.29 | 2021-2023 | Jardiance, Tradjenta |
| Otsuka America Pharmaceutical, INC. | $32.26 | 2022 | |
| Merck Sharp & Dohme LLC | $30.81 | 2019-2020 | |
| Sanofi Pasteur INC. | $24.85 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.65 | 2023 | |
| Radius Health, INC. | $24.42 | 2019 | |
| Exact Sciences Corporation | $23.52 | 2023 | Cologuard Collection Kit |
| Alexion Pharmaceuticals, INC. | $20.72 | 2023 | Ultomiris |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.75 | 2019 | |
| Lundbeck LLC | $18.50 | 2023 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $18.44 | 2023 | Farxiga |
| Dynavax Technologies Corporation | $17.81 | 2023 | Heplisav-B |
| Shire North American Group INC | $17.21 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.48 | 2022 | |
| Insulet Corporation | $16.34 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.72 | 2022 | |
| Glaxosmithkline, LLC. | $12.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmine Dorsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.